Molindone
As of the edition of 20 October 2026, Molindone is a small molecule: marketed, first approved in 1982 (US); acts on DRD2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Moban
- First approved
- 1 January 1982 (US)
- Approvals on record
- 9 in 1 region
- Holder of the most recent approval
- Chartwell Rx Sciences; 2 holders in all
- Registered trials
- 7, 2 stopped early
- Disease areas
- Mental health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DRD2 | Dopamine receptor D2 | P14416 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 4 | 2 | 0 | 2 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Endo | Acquired holder | 2003 to now |
| Chartwell Rx Sciences | Acquired holder | 2024 to now |
| Dupont Merck | Earlier holder |